Catalent Supports Rapid Development and Supply of Nocion Therapeutics’ Clinical Trial Materials for Acute and Chronic Cough Using Blow-Fill-Seal Technology
SOMERSET, N.J. – September 28, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been dosed with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate.
NTX-1175 is being developed to treat cough and has received priority review through the U.K.’s Medicines and Healthcare products Regulatory Agency, as NOC-100 has the potential to treat both chronic and acute cough – the latter a common symptom in patients with COVID-19 and associated with transmission of the SARS-CoV-2 virus.
To support this program, Catalent rapidly developed and manufactured clinical-scale batches of blow-fill-seal (BFS) nebulizer ampules at its Woodstock, Illinois facility, a process it was able to accelerate from program inquiry to clinical supply in less than six months.
“Blow-fill-seal technology offers many advantages for aseptic manufacturing. This proven platform has a low risk profile, and was ideal to accelerate development and production to meet the time frame of this project,” commented Jonathan Arnold, President, Oral and Specialty Delivery at Catalent. He added, “Our deep expertise in complex BFS formulation and fully integrated services allowed us to respond very quickly to the needs of this new and important clinical trial that also has the potential to make a positive impact on COVID-19 patients.”
Catalent’s 430,000 square-foot facility in Woodstock is the company’s center of excellence for sterile liquid fill/finish, leveraging advanced aseptic BFS manufacturing technology. The site has over 35 years’ experience in providing BFS solutions for the most complex emulsions, suspensions and biologics, and houses over 30 BFS filling suites, as well as dedicated scale-up machinery, providing flexible capacity and services from early clinical stages through commercial production for ophthalmic, respiratory, topical, and biologic markets.
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
ABOUT NOCION THERAPEUTICS
Nocion Therapeutics is a biopharmaceutical company developing novel small molecule charged sodium channel blockers, “nocions”, that selectively affect actively firing nociceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions involving cough, itch, and pain. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons. For more information, visit www.nociontx.com